W
Weiqi Pan
Researcher at Guangzhou Medical University
Publications - 37
Citations - 862
Weiqi Pan is an academic researcher from Guangzhou Medical University. The author has contributed to research in topics: Virus & Influenza A virus. The author has an hindex of 14, co-authored 30 publications receiving 597 citations. Previous affiliations of Weiqi Pan include Guangzhou Institutes of Biomedicine and Health & Chinese Academy of Sciences.
Papers
More filters
Journal ArticleDOI
An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques.
Liqiang Feng,Liqiang Feng,Qian Wang,Qian Wang,Chao Shan,Chenchen Yang,Ying Feng,Jia Wu,Liu Xiaolin,Yiwu Zhou,Ren-Di Jiang,Peiyu Hu,Xinglong Liu,Fan Zhang,Pingchao Li,Xuefeng Niu,Yichu Liu,Xuehua Zheng,Jia Luo,Jing Sun,Yingying Gu,Bo Liu,Yongcun Xu,Chufang Li,Weiqi Pan,Jincun Zhao,Changwen Ke,Xinwen Chen,Tao Xu,Nanshan Zhong,Guan Suhua,Zhiming Yuan,Ling Chen,Ling Chen +33 more
TL;DR: A replication-incompetent adenovirus based vaccine expressing SARS-CoV-2 spike is generated, protection from infection in non-human primates is shown, and the immune response after intramuscular and intranasal vaccination is analyzed.
Journal ArticleDOI
Visualizing influenza virus infection in living mice
Weiqi Pan,Zhenyuan Dong,Feng Li,Feng Li,Weixu Meng,Weixu Meng,Liqiang Feng,Xuefeng Niu,Chufang Li,Qinfang Luo,Zhengfeng Li,Caijun Sun,Ling Chen,Ling Chen +13 more
TL;DR: This work reports the visualization of influenza viral infection in living mice using an engineered replication-competent influenza A virus carrying luciferase reporter gene to enable real-time study of influenza virus infection and effects of antiviral therapeutics in living animals.
Journal ArticleDOI
Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.
Qinhai Ma,Weiqi Pan,Run-Feng Li,Bin Liu,Chufang Li,Yuqi Xie,Zhoulang Wang,Jin Zhao,Haiming Jiang,Jicheng Huang,Yongxia Shi,Jun Dai,Kui Zheng,Xiaobo Li,Zifeng Yang +14 more
TL;DR: Findings indicate that LS could inhibit SARS-CoV-2 virus infection via downregulating the expression of inflammatory cytokines induced virus and regulating the activity of NF-κB/MAPK signaling pathway in vitro, making its promising candidate treatment for controlling COVID-19 disease.
Journal ArticleDOI
Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway.
Qinhai Ma,Runfeng Li,Weiqi Pan,Wenbo Huang,Bin Liu,Yuqi Xie,Zhoulang Wang,Chufang Li,Haiming Jiang,Jicheng Huang,Yongxia Shi,Jun Dai,Kui Zheng,Xiaobo Li,Min Hui,Li Fu,Zifeng Yang,Zifeng Yang +17 more
TL;DR: Investigation of the antiviral and anti-inflammatory activities of KD-1 against the novel SARS-CoV-2 and H coV-229E indicated that KD- 1 protected against virus and can thus be used as a novel strategy for controlling coronavirus 2019.
Journal ArticleDOI
Potent Neutralization of Influenza A Virus by a Single-Domain Antibody Blocking M2 Ion Channel Protein
Guowei Wei,Weixu Meng,Weixu Meng,Haijiang Guo,Weiqi Pan,Weiqi Pan,Jinsong Liu,Tao Peng,Ling Chen,Ling Chen,Chang-You Chen +10 more
TL;DR: Screens against native M2 ion channel protein demonstrate for the first time that a neutralizing antibody against M2 with broad specificity is achievable, and M2-7A may have potential for cross protection against a number of variants and subtypes of influenza A viruses.